Calcitriol Supplementation in COVID-19 Patients

• Status: Not yet recruiting
• Trial end date: 2022-09-19
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, open label study to evaluate the efficacy and safety of calcitriol supplementation in COVID-19 patients with vitamin D deficiency.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Calcitriol

Criteria

Inclusion Criteria:

1. Hospitalized symptomatic COVID-19 patients;

2. COVID-19 nucleic acid Ct value < 28 (both orf1ab gene Ct value and N gene Ct value < 28);

3. Vitamin D deficiency: 25OHD ≤ 20ng/ml;

4. Age: 18-70 years old;

Exclusion Criteria:

1. Asymptomatic COVID-19 patients ；

2. Hypercalcemia;

3. History of primary hyperparathyroidism;

4. History of triple hyperparathyroidism;

5. Patients who are allergic to calcitriol;

6. Pregnant or lactating women;

7. Patients with severe heart or lung diseases or tumor history;

8. Patients already taking vitamin D or its similar preparations;

9. Participants in other interventional clinical studies (including taking paxlovid);

10. Patients with renal insufficiency (eGFR<60ml/min/1.73m2);

11. Patients considered unsuitable for this study by the investigator；